ProCE Banner Activity

Therapeutic Strategies for HER2-Positive Breast Cancer Today: Frequently Asked Questions

Clinical Thought

Read this commentary for expert responses to audience questions from a recent live webinar on the current treatment of HER2-positive breast cancer.

Released: March 24, 2023

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research), Division of Medical Oncology
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Puma Biotechnology, Inc.

Seagen Inc.

Faculty Disclosure

Primary Author

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research), Division of Medical Oncology
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Aditya Bardia, MD, MPH: consultant/advisor: Daiichi Sankyo/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, Sanofi; researcher (paid to institution): Daiichi Sankyo/AstraZeneca, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Radius Health, Sanofi.

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Erika P. Hamilton, MD: researcher (paid to institution): AbbVie, Acerta, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan-Florentine, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR, Ellipses, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind, Leap, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova, Oncothyreon, ORIC, Orinove, Orum, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque, Treadwell, Verastem, Zenith, Zymeworks; consultant/advisor: Arcus, AstraZeneca, Daiichi Sankyo, Ellipses, Greenwich LifeSciences, iTeos, Janssen, Lilly, Loxo, Mersana, Novartis, Olema, Orum, Pfizer, Relay Therapeutics, Roche/Genentech, SeaGen, Stemline, Tubulis, Verascity Science.